Granules India Ltd (GRANULES.NS) trades near ₹583 with Q3 FY26 results scheduled for January 23, 2026, consensus expecting revenue ₹1,377 Cr (+17.7% YoY), PAT ₹118 Cr (+21% YoY), EBITDA ₹174 Cr (+15%). EGM held January 22 for ₹1,763 Cr fundraising approval.
Detailed Technical Rationale (Buy-Side)
Granules exhibits oversold bounce potential at ₹583.10 with RSI(14) 38.16 sell zone but CCI(14) -109 exhaustion signal, pivot ₹487.7 reference पर S1 ₹473.54 / S2 ₹466.77 / S3 ₹454.54 strong support cluster aligning with 200-day SMA ₹514-520 neutral extension.
All 12 MAs strong sell (10-day ₹602 / 50-day ₹575) लेकिन high volatility ATR 4.60 confirms capitulation bottom during pharma rotation. Volume accumulation targets R1 ₹597 / R2 ₹612 / R3 ₹621 resistance (2-6% upside) with stop below S3 ₹454 offering 1:4 risk-reward pre-results catalyst.
Detailed Fundamental Analysis
Granules integrated pharma player Q2 FY26 revenue ₹1,297 Cr (+35% YoY), EBITDA ₹278 Cr margins 21.4%, PAT growth via US API/PFI exports 70% mix, debt reduction trajectory net cash positive potential. ROE 15%+, 10 ANDA filings pipeline strengthens complex generics moat.
Fundraising ₹1,763 Cr (warrants ₹1,463 Cr @ ₹585 + equity ₹300 Cr) funds capex/capacity expansion USFDA compliance, undervalued peers vs Nifty Pharma despite cyclical pressures, dividend payout history supports shareholder returns post-results.
Micro & Macro View
Micro View: Granules US-centric growth (90% exports), formulation expansion APIs/PFIs/FD, regulatory wins (FDA tentative approvals), new facilities commissioning offset Q2 one-offs, sticky customer concentration top-5 60% revenue stable.
Macro View: US pricing reforms tailwinds complex generics, PLI scheme electronics/pharma incentives, rupee depreciation export boost; risks FDA observations, raw material volatility but hedged via long-term contracts.
Key News Events & Impacts
Q3 Results Jan 23, 2026 (Call 6 PM IST): Revenue +17.7% YoY ₹1,377 Cr, PAT +21% ₹118 Cr, EBITDA +15% ₹174 Cr expected on export volumes/margins. Watch USFDA updates, fundraising utilization guidance.
EGM Jan 22, 2026: Approved ₹1,763 Cr preferential issue (promoters/institutions), positive expansion signal but equity dilution ~10% risk.
Key Watch Levels: Pre-results ₹600 resistance break → ₹650 target; sub ₹473 breakdown → ₹450 test.
Additional Important Points
Q2 strong execution despite headwinds validates guidance.
180-day exclusivity tentative FDA approvals pipeline catalyst.
Corrigendum EGM notice ensures compliance transparency.
Nifty Pharma underperformance creates entry opportunity.
Disclaimer & Disclosure
Disclaimer:
This constitutes research recommendation under SEBI (Research Analyst) Regulations 2014. Investogainer Research SEBI-registered RA; past performance no future guarantee. Independent verification required; no liability for losses.
Disclosure: No position/holding in GRANULES as on Jan 22, 2026. Targets from technical/fundamental models. Stop-loss mandatory. Market risks apply.